[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574730":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":18,"responsibleParty":50,"collaborators":53,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":7,"studyType":74,"phases":7,"briefSummary":75,"conditions":76,"keywords":83,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Manitoba","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Not applicable- observational study","It's an observational study. Participants are not assigned an intervention as part of the study.",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Abdullah A Maruf, BPharm, MPharm, PhD","CONTACT","204-318-2575","abdullah.maruf@umanitoba.ca",[19,36],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Shared Health Facilities","RECRUITING","Winnipeg","Manitoba","R3C 3H8","Canada","CA",{"type":28,"coordinates":29},"Point",[30,31],-97.14704,49.8844,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":16,"phoneExt":7,"email":17},"Abdullah Al Maruf, PhD, M.Pharm., B.Pharm",{"facility":37,"status":21,"city":22,"state":23,"zip":38,"country":25,"countryCode":26,"cosmosGeoPoint":39,"geoPoint":41,"contacts":42},"University of Manitoba College of Pharmacy","R3E 0T5",{"type":28,"coordinates":40},[30,31],{"lat":31,"lon":30},[43,45,48],{"name":44,"role":15,"phone":16,"phoneExt":7,"email":17},"Abdullah Al Maruf, PhD, M.Pharm, B.Pharm",{"name":46,"role":15,"phone":7,"phoneExt":7,"email":47},"Mahin Hasan, MSc, BSc","hasanm33@myumanitoba.ca",{"name":44,"role":49,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Abdullah Al Maruf","Assistant Professor",[54,56,58],{"name":55,"class":6},"Health Sciences Centre Foundation, Manitoba",{"name":57,"class":6},"Children's Hospital Research Institute of Manitoba",{"name":59,"class":6},"University of Calgary","100574730","pharmacogenomics-of-selective-serotonin-reuptake-inhibitor-ssri-induced-behavioural-activation-100574730",false,"NCT06763081","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation in Children and Youth (PGx-SImBA)","PGx-SImBA","Inclusion criteria: Participants will be eligible for participation if all of the following are true.\n\n* Resident of Manitoba\n* Age, 6 - 24 years\n* Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)\n* Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram \\[Celexa\\], Escitalopram \\[Cipralex\\], Fluoxetine \\[Prozac\\], Fluvoxamine \\[Luvox\\], Sertraline \\[Zoloft\\], Paroxetine \\[Paxil\u002FPlaxil CR\\]) therapy\n* \\[Cases Only\\] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug\n* \\[Controls Only\\] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks\n\nExclusion criteria: Participants will be excluded from participation if any of the following are true.\n\n* Inability of parent\u002Flegal guardian\u002Fmature minors to give informed consent\n* Inability of the child (6 - 13 years) to give informed assent\n* Unwillingness of the child to provide a saliva sample for genetic analysis\n* Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder\n* History of liver or bone marrow (hematopoietic cell) transplant.","ALL","6 Years","24 Years",{"count":72,"type":73},160,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[77,78,79,80,81,82],"Behavioral Activation","Major Depressive Disorder","Anxiety Disorders","Antidepressant Drug Adverse Reaction","Obsessive Compulsive Disorder (OCD)","Major Depression",[84,85,86,87,88,89,90,91,92,93,94,95,96,97,98],"SSRI","Depression","OCD","Anxiety","Antidepressants","Children","Adolescents","Mood Disorders","Drug-induced Adverse Events","Youth","Mental Illness","Mental disorders","Drug-Related Side Effects and Adverse Reactions","Selective Serotonin Reuptake Inhibitor","Disinhibition","2025-09-01",{"date":101,"type":102},"2025-09-08","ACTUAL",{"date":104,"type":102},"2025-03-01",{"date":106,"type":73},"2030-12-31",{"name":5,"class":6},2]